BV14 does not increase vascular permeability in vivo.

Control nu/nu (CD-1)BR mice (white columns) or mice injected with C6 glioma (striped columns) were treated with nonimmune IgG or BV13 or BV14. Every 3 days mice received the indicated amounts of mAbs. At 10 days after tumor implantation, mice were tested for Evans blue leakage in lungs. While BV13 increased permeability to a significant extent, BV14 was essentially inactive. Data are expressed as percentage increase in Evans blue content in comparison to mice treated with equivalent doses of nonimmune rat IgG. Data are means ± SEM of 3 experiments performed in triplicate.